Kimberley S. Mak, MD, MPH
Assistant Professor
Boston University School of Medicine
Dept of Radiation Oncology

MD, Harvard Medical School
MPH, Harvard School of Public Health




Kimberley S. Mak, MD, MPH, is an Assistant Professor of Radiation Oncology at the Boston University School of Medicine and its affiliate Boston Medical Center. She received her MPH from Harvard School of Public Health (2014), MD from Harvard Medical School (2010) and AB summa cum laude in Biochemical Sciences from Harvard College (2005). Dr. Mak completed an internship in Internal Medicine at Brigham and Women's Hospital (2011), followed by residency in the Harvard Radiation Oncology Program (2015), training at Massachusetts General Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Children's Hospital of Boston, and Boston Medical Center. Dr. Mak has board certification in Radiation Oncology by the American Board of Radiology. She speaks English and Cantonese. Her specialties include thoracic, gastrointestinal, breast, and musculoskeletal malignancies. She leads the Cyberknife® radiosurgery program for thoracic and gastrointestinal malignancies.

Her research interests include patient-reported outcomes including quality of life; disparity outcomes research; translational research; intensity-modulated and image-guided radiotherapy; CyberKnife® stereotactic radiotherapy; and functional imaging in radiotherapy. She has training and experience in biostatistics, epidemiology, decision analysis, meta-analysis, clinical trial design, and molecular and cell biology laboratory work.

Member
Boston University
BU-BMC Cancer Center


Boston Medical Center


VA Boston Healthcare System



2008-2009 Howard Hughes Medical Institute: Medical Student Research Training Fellowship
2005 Harvard College: Phi Beta Kappa

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Moeller AR, Clancy PE, Qureshi MM, Guill JR, Dyer MA, Hirsch AE, Truong MT, Mak KS. Placard in Hand: A Simple, Inexpensive Intervention to Improve On-Treatment Visit Compliance in a Safety Net Radiation Oncology Patient Population. JCO Oncol Pract. 2020 Nov; 16(11):e1272-e1281.View Related Profiles. PMID: 32936711
     
  2. Yu S, Xu H, Sinclair A, Zhang X, Langner U, Mak K. Dosimetric and planning efficiency comparison for lung SBRT: CyberKnife vs VMAT vs knowledge-based VMAT. Med Dosim. 2020 Winter; 45(4):346-351.View Related Profiles. PMID: 32532613
     
  3. Shah NK, Qureshi MM, Dyer MA, Truong MT, Mak KS. Optimal Radiotherapy Dose in Anal Cancer: Trends in Prescription Dose and Association with Survival. J Gastrointest Cancer. 2020 Mar 09.View Related Profiles. PMID: 32152823
     
  4. Asokan S, Sridhar P, Qureshi MM, Bhatt M, Truong MT, Suzuki K, Mak KS, Litle VR. Presentation, Treatment, and Outcomes of Vulnerable Populations With Esophageal Cancer Treated at a Safety-Net Hospital. Semin Thorac Cardiovasc Surg. 2020 Summer; 32(2):347-354.View Related Profiles. PMID: 31866573
     
  5. Yan SX, Qureshi MM, Dyer M, Truong MT, Mak KS. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer. Lung Cancer. 2019 05; 131:147-153.View Related Profiles. PMID: 31027693
     
  6. Sridhar P, Bhatt M, Qureshi MM, Asokan S, Truong MT, Suzuki K, Mak KS, Litle VR. Esophageal Cancer Presentation, Treatment, and Outcomes Vary With Hospital Safety-Net Burden. Ann Thorac Surg. 2019 05; 107(5):1472-1479.View Related Profiles. PMID: 30605641
     
  7. Yan SX, Qureshi MM, Suzuki K, Dyer M, Truong MT, Litle V, Mak KS. Definitive treatment patterns and survival in stage II non-small cell lung cancer. Lung Cancer. 2018 10; 124:135-142.View Related Profiles. PMID: 30268452
     
  8. Mak KS, Lee SW, Balboni TA, Marcus KJ. Clinical outcomes and toxicity following palliative radiotherapy for childhood cancers. Pediatr Blood Cancer. 2018 Jan; 65(1). PMID: 28853208
     
  9. Giacalone NJ, Qureshi MM, Mak KS, Kirke D, Patel SA, Shah BA, Salama AR, Jalisi S, Truong MT. Adjuvant chemoradiation does not improve survival in elderly patients with high-risk resected head and neck cancer. Laryngoscope. 2018 04; 128(4):831-840.View Related Profiles. PMID: 28833217
     
  10. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017 Jun 01; 3(6):827-831. PMID: 27892978; DOI: 10.1001/jamaoncol.2016.3834;
     
Showing 10 of 27 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 27 publications over 10 distinct years, with a maximum of 6 publications in 2017

YearPublications
20051
20081
20102
20143
20152
20165
20176
20182
20192
20203

Mentorship for students interested in oncology, radiation oncology, lung cancer, gastrointestinal cancer, gynecologic cancers, patient-reported outcomes including quality of life, disparities outcomes research, and outcomes research.

Available to Mentor as: (Review Mentor Role Definitions):
  • Career Mentor
  • Project Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

818 Harrison Ave
Boston MA 02118
Google Map


Mak's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department